- TRINTELLIX is the first antidepressant to include head-to-head data in its labeling that showed improvement in treatment-emergent sexual dysfunction in patients with MDD who switched from certain SSRI treatments
- This is the second time this year the FDA has approved a TRINTELLIX labeling update
PR Newswire
DEERFIELD, Ill., Oct. 22, 2018